PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia-Reference-Cited by-同舟云学术

PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia

Published:2016-06-21 Issue:1 Volume:57 Page:7-32
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Ito Matthew K.¹²,Santos Raul D.³

Affiliation:

1. Sanofi US; Bridgewater; NJ USA

2. Oregon State University/Oregon Health and Science University; College of Pharmacy; Portland OR, USA (during initial development of this article)

3. Lipid Clinic, Heart Institute (InCor), University of Sao Paulo Medical School Hospital, and Preventive Medicine Center and Cardiology Program; Hospital Israelita Albert Einstein; Sao Paulo Brazil

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference97 articles.

1. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications;Tabas;Circulation,2007

2. National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1-full report;Jacobson;J Clin Lipidol,2015

3. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis;Boekholdt;JAMA,2012

4. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality;Emerging Risk Factors Collaboration;JAMA,2009

5. PROCARDIS Consortium. Genetic variants associated with Lp(a) lipoprotein level and coronary disease;Clarke;N Engl J Med,2009

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Far-infrared irradiation increases the uptake of LDL cholesterol by downregulating PCSK9 through the activation of TRPV4 calcium channels in HepG2 cells;Biochemical and Biophysical Research Communications;2024-09

2. Current and emerging monoclonal antibodies for treating familial hypercholesterolemia in children;Expert Opinion on Biological Therapy;2024-03-21

3. Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial;European Heart Journal;2023-08-28

4. Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol;Journal of Clinical Medicine;2023-08-02

5. Familial Hypercholesterolemia in Children. The Current State of the Problem;Current Pediatrics;2023-07-08